DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Eli Lilly's Zepbound - 1 Anthony Petrone - 1 Medical's - 1 Eli Lilly - 1 Tim Herbert - 1 Zepbound - 1 Herbert - 1 FactSet - 1
Top related locs:
U.S
Top related orgs:
Novo Nordisk's - 1 Mizuho Securities - 1 CNBC - 1 Systems - 1 Inspire - 1 American Diabetes Association - 1 Drug Administration - 1 National Institutes of Health - 1

Search resuls for: "Anthony Petrone"


2 mentions found


☆ Ozempic doesn't make everyone thin. That opens up an opportunity for some stocks
  + stars: | 2024-05-27 | by ( Christina Cheddar Berk | In | ) www.cnbc.com   time to read: +7 min
Or, in other cases, it can open the door to new options for the treatment of obstructive sleep apnea. Treating obesity and addressing sleep apnea Sleep apnea is a serious sleep disorder that results in interrupted breathing, preventing patients — and even their sleeping partners — from getting restful and restorative sleep. Obstructive sleep apnea, the most common form, occurs when muscles in the throat relax and collapse preventing air flow. Before qualifying for the device, patients usually need to have tried treatment with a CPAP machine and an oral device and been unsuccessful. He downgraded Inspire shares to hold at the beginning of the year due to this uncertainty he was anticipating.
Persons: Eli Lilly's Zepbound, Anthony Petrone, Medical's, Eli Lilly, Tim Herbert, Zepbound, Herbert, FactSet, Petrone, UnitedHealth, Jonathan Block Organizations: Novo Nordisk's, Mizuho Securities, CNBC, Systems, Inspire, American Diabetes Association, Drug Administration, National Institutes of Health, BMI Locations: U.S
☆ This maker of CPAP machines can gain market share as rival deals with a recall, Mizuho says
  + stars: | 2023-04-14 | by ( Brian Evans | ) www.cnbc.com   time to read: +1 min
An ongoing product recall for one of ResMed's top competitors opens up a big opportunity for the continuous positive airway pressure (CPAP) equipment maker, according to Mizuho. Philips Respironics, a rival CPAP hardware maker, is still contending with a 2021 recall of its products, leaving the door open for ResMed to grow its market share, Petrone said. "In aggregate, we see RMD settling at nearly ~60% permanent sleep device share, up from ~50%, as a result of the extended Philips CPAP recall," Petrone wrote on Thursday. Petrone added that ResMed has maintained its market share from a decline in Philips for longer than expected. RMD YTD mountain RMD in 2023 Mizuho pointed toward proprietary survey data that indicated pent-up demand and a rebound in U.S. volume.
0 next >>
Total: 2